MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS
Article
Bell, Erica H, Zhang, Peixin, Fisher, Barbara J et al. (2016). MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS
. NEURO-ONCOLOGY, 18(suppl_6), vi115-vi115. 10.1093/neuonc/now212.478
Bell, Erica H, Zhang, Peixin, Fisher, Barbara J et al. (2016). MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS
. NEURO-ONCOLOGY, 18(suppl_6), vi115-vi115. 10.1093/neuonc/now212.478